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APRIL = a proliferation-inducing ligand, TNFSF13a; BAFF = B cell-activating factor of the tumor necrosis factor family, TNFSF13b; BAFF-R = BAFF
receptor, also called BR-3, TNFRSF13c; BCMA = B cell maturation antigen, TNFRSF17; BCR = B cell receptor; CTLA4 = cytotoxic T lymphocyte-
associated antigen 4; SLE = systemic lupus erythematosus; T1 = transitional type 1; TACI = transmembrane activator and calcium modulator ligand
interactor, TNFRSF13b; TNF = tumor necrosis factor; TWEAK = TNFSF12.
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Introduction
B cells are important in the pathogenesis of autoimmune
disease. They produce autoantibodies that mediate tissue
injury, they function as antigen-presenting cells that
present epitopes of self-antigen to autoreactive T cells,
and they produce soluble mediators involved in the
organization of lymphoid tissues and in the initiation and
perpetuation of inflammatory processes [1]. In some
autoimmune diseases, B cells migrate to inflamed sites,
where they act as local effector cells [2,3]. Because
autoreactive B cells have a role in both the inductive and
effector arms of autoimmune disease, there is
considerable interest in B cell depletion or modulation as
a therapeutic strategy.
BAFF, APRIL and their receptors
The B cell survival factor BAFF (BLyS; TNFSF13b), a
member of the TNF family, is expressed on the surface of
monocytes, dendritic cells [4,5], neutrophils [6], stromal
cells [7] and activated T cells [8], and in the serum as a
biologically active homotrimer [9]. BAFF-deficient mice are
profoundly deficient in B cells, whereas BAFF transgenic
mice have increased B cell numbers and develop a lupus-
like syndrome [10]. Thus, levels of BAFF must be tightly
regulated to maintain B cell survival without triggering
autoimmunity.
B cells express three different BAFF receptors (trans-
membrane activator and calcium modulator ligand interactor
[TACI; TNFRSF13b], BCMA [B cell maturation antigen;
TNFRSF17] and BAFF-R [BAFF receptor; TNFRSF13c])
at various times during their differentiation (Figs 1 and 2).
BCMA is expressed on transitional type 1 (T1) cells [11]
and on plasma cells [12,13], whereas TACI and BAFF-R
are expressed on transitional type 2/3 and mature B cells
[11]. BAFF-R is upregulated by B cell receptor (BCR)
ligation on mature B cells [11] and is expressed on resting
memory B cells [12]. BAFF-R mediates most BAFF-
dependent functions in the naive B cell population [11],
whereas BCMA is needed for the optimal generation of
long-lived plasma cells [13]. TACI has mixed positive and
negative B cell regulatory functions; TACI-deficient mice
have decreased serum IgM and decreased IgM responses
to T-independent antigens, yet they have increased B cell
numbers and develop an autoimmune phenotype [14].
Engagement of TACI on B cells results in a decreased
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Abstract
It is increasingly recognized that B cells have multiple functions that contribute to the pathogenesis of
autoimmunity. Specific targeting of B cells might therefore be an appropriate therapeutic intervention.
The tumor necrosis factor-like molecule BAFF (BLyS) is a key B cell survival factor and its receptors
are expressed on most peripheral B cells. Several different BAFF antagonists are under development
and in early clinical trials. We review here the rationale for BAFF blockade, and its predicted
mechanism of action in autoimmune diseases.
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proliferative response to lipopolysaccharide or anti-CD40L
stimulation and an increase in apoptosis [14], but the
signaling pathways that mediate this effect have not yet
been elucidated. In addition, TACI might act as a sink for
BAFF and prevent its binding to BAFF-R.
TACI and BCMA also bind APRIL (for ‘a proliferation-
inducing ligand’), a molecule homologous to BAFF, which
is not necessary for normal B cell development [15] but
induces B cell proliferation, class switching and survival
[12,16]. To further complicate matters, APRIL and BAFF
can form heterotrimers [17] and the extracellular domain
of APRIL can form a hybrid molecule with the intracellular
domain of TWEAK (TWE-PRIL; TNFSF12) as a result of
alternative splicing [18]. The physiologic role of these
mixed molecules remains to be defined. Finally, ∆BAFF is
an alternatively spliced form of BAFF that does not bind to
BAFF receptors. When ∆BAFF is co-expressed with
BAFF, it acts in a dominant negative fashion both because
heterotrimers of ∆BAFF/BAFF are not functional and
because their formation results in intracellular retention of
BAFF [19] (Fig. 1).
Function of BAFF and APRIL
BAFF prolongs B cell survival by regulating the expression
of Bcl-2 gene family members [20]. BAFF might also
enhance signaling through the BCR by upregulating
expression of the BCR co-receptors CD21 and CD19 and
by potentiating BCR-mediated phosphorylation of CD19
[21,22]. Recent studies suggest that the levels of BAFF
can influence the selection and differentiation of
autoreactive B cells in the periphery [23,24]; this should
be a fruitful area for further investigation.
Germinal centers are shorter-lived in BAFF-deficient mice
than in wild-type mice. Nevertheless, somatic mutation
and class switching occur in these attenuated germinal
centers and the antibody response to T-dependent
antigens is of lower titer but not of lower affinity [25].
BAFF and APRIL prolong the survival but do not induce
the proliferation of memory B cells in vitro [12]. However,
Figure 1
Interactions of BAFF and its homologs with the three BAFF receptors.
Sites of action of potential blockers are described in Table 1. APRIL, a
proliferation-inducing ligand; BAFF-R, BAFF receptor; BCMA, B cell
maturation antigen; ∆BAFF, alternatively spliced form of BAFF that
does not bind to BAFF receptors; TACI, transmembrane activator and
calcium modulator ligand interactor; TWE-PRIL, a fusion protein of
TWEAK (TNFSF12) and APRIL.
Figure 2
Stages of B cell development and expression of BAFF receptors. The BAFF receptor expressed is shown in the box (1, B cell maturation antigen
[BCMA]; 2, transmembrane activator and calcium modulator ligand interactor [TACI]; 3, BAFF receptor [BAFF-R]). A broken line indicates stages
of differentiation that can occur independently of BAFF. The necessity of BAFF for the survival of established memory cells or of long-lived plasma
cells is not yet certain.199
our own data suggest that memory cells survive in vivo in
the presence of BAFF blockade [26]. BAFF and APRIL
enhance the survival of plasmablasts, but there are still
conflicting data about whether they are required for the
survival of long-lived plasma cells [12,13]. Finally, the B1
compartment seems to be independent of both BAFF and
APRIL [11,27,28].
The role of BAFF and APRIL in T cell co-stimulation is
controversial [26,29]. BAFF enhances T cell proliferation
in vitro [8] but T cell numbers are normal in BAFF-deficient
mice [27]. T cells are expanded twofold in number and
seem activated in BAFF transgenic mice [10], but this
might be secondary to B cell expansion rather than a
direct effect on T cells. T cells from TACI-deficient mice
hyperproliferate in response to anti-CD3 and BAFF,
suggesting that TACI might in fact negatively regulate T
cell function [14]. In contrast, APRIL seems to enhance T
cell proliferation [30], perhaps through a different
receptor.
BAFF antagonists for autoimmune diseases
BAFF and APRIL levels are increased in patients with
systemic lupus erythematosus (SLE) [17] and correlate
with titers of autoantibodies [31] and disease activity
scores [32]. Both BAFF and APRIL are found in the
synovial fluid of patients with rheumatoid arthritis, in whom
they might prolong the survival of pathogenic B cells [33].
BAFF is also expressed in salivary glands of patients with
Sjögren’s syndrome [34] and in the central nervous system
of mice with experimental autoimmune encephalomyelitis
[35]. These findings, together with the observation that
BAFF receptors are expressed on nearly all B cells [12,13],
suggest that BAFF antagonism might be a useful
therapeutic strategy for autoimmune diseases in which B
cells have a pathogenic role [36]. Pre-clinical data in mice
show that BAFF antagonists substantially delay the onset
of disease in SLE-prone NZB/W mice [26,28,37] and
prevent collagen-induced arthritis in DBA1 mice [29].
Two classes of human BAFF antagonist are being
developed (Table 1). The first is a human antibody (anti-
BLyS; LymphoStat-B) that binds soluble BAFF and
prevents its interaction with all three receptors with
equivalent potency [38]. It is currently in Phase 2 clinical
trial for human SLE and rheumatoid arthritis. The second
class of BAFF antagonist is a fusion protein of one of the
BAFF receptors with immunoglobulin. Both TACI-Ig and
BAFF-R-Ig are under development. These might have
different properties, because TACI-Ig blocks the action of
both BAFF and APRIL, whereas BAFF-R-Ig blocks only
BAFF. LymphoStat-B might differ in its effects from BAFF-
R-Ig because it does not block membrane-bound BAFF
[38]. Human BCMA-Ig binds both BAFF and APRIL but it
is sevenfold to eightfold less potent than BAFF-R-Ig and
might therefore not be a useful therapeutic agent [39]. A
BCMA-Ig mutant that blocks only APRIL has been
generated and might be useful for further dissecting the
function of APRIL in autoimmunity [40]. Finally, a 26 amino
acid domain of BAFF-R that forms a β-turn structure has
been found to bind BAFF with the same affinity as full-
length BAFF-R. A six amino acid peptide derived from this
domain is sufficient to block NF-κB2/p52 induction by
BAFF in primary B cells. TACI and BCMA have
homologous sequences in this region, so peptide
antagonists might be derived for all three receptors [37].
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Table 1
List of current and potential BAFF antagonists
Blocks BAFF
Therapeutic agent Soluble Membrane Blocks APRIL Current status Reference
LymphoStat-B (Human Genome Sciences) + −− Phase II clinical trialsa [38]
BAFF-R-Ig (Biogen Idec) + + − In development [39]
TACI-Ig (ZymoGenetics Serono) + + + Phase I clinical trials [28]
BCMA-Ig +b +/− + – [39]
Mutated BCMA-Ig −− + – [40]
MiniBR3 (BAFF-R) + + − Pre-clinical [37]
Peptidomimetics of:
BAFF-R + + − Pre-clinical [37]
TACI + + + Hypothetical [37]
BCMA + + + Hypothetical [37]
aSystemic lupus erythematosus and rheumatoid arthritis. bLow affinity for BAFF. BAFF-R, BAFF receptor; BCMA, B cell maturation antigen; TACI,
transmembrane activator and calcium modulator ligand interactor.200
Mechanism of action of BAFF blockade
BAFF blockade mediates profound effects on B cells in
mice. Within 1–2 weeks of administration of TACI-Ig or
BAFF-R-Ig to normal mice, the spleen and lymph nodes
decrease in size and the B cell frequency decreases by
50%. The decrease in T2, marginal-zone and follicular B
cells is relatively greater than the decrease in T1 cells, but
B1 cells are unaffected ([28] and M Ramanujam,
unpublished data). Germinal center formation is impaired
[25], as is the generation of memory responses [11].
However, established memory cells can survive a short
period of BAFF blockade [26]. One study has reported a
decrease in the frequency of antigen-specific bone
marrow plasma cells after TACI-Ig treatment [13].
Recovery of B cells takes several months after the
cessation of treatment.
We have found that in normal mice TACI-Ig induces a
reversible decrease in the serum levels of IgM and IgG1
and impairs primary IgM immune responses to a T-
dependent antigen, but BAFF-R-Ig has little effect on
serum immunoglobulin levels. In SLE-prone NZB/W mice,
which have a marked polyclonal increase in serum IgM,
TACI-Ig, but not BAFF-R-Ig, normalizes serum IgM levels
for months after a short treatment course. Nevertheless,
both agents delay disease onset. BAFF blockade has little
effect on total serum IgG in NZB/W mice. In the NZB/W
SLE model, both fusion proteins have only modest effects
on the emergence of IgG anti-double-stranded DNA
antibodies but they induce B cell depletion and a marked
delay in the expansion of activated and memory T cells.
The addition of a short course of cytotoxic T lymphocyte-
associated antigen 4 (CTLA4)Ig to TACI-Ig results in a
decrease in the serum levels of IgG and of autoantibodies,
perhaps because T cell-derived cytokines augment the
effect of BAFF on plasma cell survival [12]. Despite some
differences in the immunologic effects of TACI-Ig and
BAFF-R-Ig, both reagents delay disease onset and death
by 4–5 months when given before the emergence of
nephritis in NZB/W F1 mice, and the combination of TACI-
Ig and CTLA4Ig can even reverse established nephritis in
this model ([26] and M Ramanujam and A Davidson,
unpublished data). In the collagen-induced arthritis model,
TACI-Ig given just before disease onset inhibits both anti-
collagen antibodies and T cell proliferative and cytokine
responses to collagen and markedly attenuates disease
[29].
The effect of a 4-week course of anti-BLyS in primates is
similar to that of BAFF-R-Ig, with a decrease in B cells in
secondary lymphoid organs but no effect on serum Ig
[38]. A Phase 1 study of anti-BLyS in patients with SLE
showed that the agent has a half-life of 13–17 days, that it
reduces the number of circulating B cells and that, in
some patients, serum levels of anti-DNA antibodies
decreased after treatment [41].
The extensive information available about BAFF and
APRIL allows us to make several predictions about the
effects of BAFF blockade in autoimmune disease. The first
is that BAFF blockade will deplete B2 cells but not B1
cells. B2 cells are bone marrow-derived B cells that
differentiate into either marginal-zone or follicular cells in a
BAFF-dependent manner. B1 cells might constitute a
separate self-renewing lineage that derives from the fetal
liver, is located predominantly in the peritoneal cavity and
does not seem to depend on BAFF for survival [42,43]
(Fig. 2). Thus, autoimmune diseases in which B1 cells
have a dominant role might be resistant to BAFF blockade.
Second, diseases in which BCMA-expressing plasma
cells produce pathogenic antibodies might be more
sensitive to blockade with TACI-Ig than with selective
BAFF blockers because APRIL can support the survival of
these cells. TACI-Ig might also be more effective for
diseases in which short-lived extrafollicular plasma cells
produce IgM autoantibodies. In contrast, if autoantibody-
producing plasmablasts are continuously newly formed
from memory cells or naive cells that predominantly
express BAFF-R, blockade of BAFF alone should be
effective. Third, the immunoglobulin repertoire of newly
emerging B cells may be altered by BAFF blockade
because the survival of transitional B cells will be
decreased and because of possible alterations in the
strength of the BCR signal, but the repertoire of
established memory cells is unlikely to be altered. Fourth,
depletion of B cells by blockade of BAFF should have
indirect effects on other cell types and on inflammatory
mediators, some of which might improve disease activity
independently of effects on autoantibody production.
These include decreased antigen presentation to T cells,
decreased epitope spreading, decreased cytokine
secretion, decreased immune complex formation and
decreased infiltration of target organs. Finally, BAFF
blockade might synergize with agents that block T cell
activation (Fig. 3). It is important to explore these
hypotheses in autoimmune individuals and in rodent auto-
immunity models because intrinsic B cell hyperreactivity,
the provision of excessive T cell help and the presence of
inflammatory mediators might alter the normal
dependence of B cells on BAFF or APRIL and thus the
response to blockade.
Is BAFF blockade immunosuppressive?
An obvious concern about BAFF blockade is its
immunosuppressive potential. TACI-Ig blocks the T-
independent response of marginal-zone B cells to bacterial
antigens [44] but does not block the response of B1 cells
(M Ramanujam, unpublished data). The effect of BAFF-R-Ig
on anti-bacterial responses has not yet been reported, but
primary IgM responses to both T-dependent and T-
independent antigens seem intact in BAFF-R-deficient
mice [45]. The effect of BAFF blockade on anti-bacterial
responses is clearly of concern for patients with SLE, who
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are prone to infections with encapsulated organisms. The
absence of BAFF or BAFF-R results in diminished, but not
absent, IgG responses to T-dependent antigens [25,45].
The physiologic impact of this decrease with regard to
protective immune responses remains to be determined.
Finally, the effect of BAFF blockade on T cell responses to
infectious agents needs to be investigated further.
Conclusions
BAFF is a rational target for therapy of autoimmune
diseases, and several different antagonists that may have
different properties are being developed. B cell depletion is
expected to have multiple direct and indirect effects on the
autoimmune response. The potential ability of BAFF
blockade to modulate memory B cells and plasmablasts
might result in therapeutic benefit for diseases in which
pathogenic autoantibodies derive from these cells. Analysis
of the effects of BAFF blockade in vivo might yield
important insights into the pathogenesis of autoimmune
diseases. Much remains to be learned about the
appropriate clinical use of this new class of drugs, including
its safety profile and its ability to synergize with other
conventional or biological immunosuppressive agents.
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